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Abstract 
Objective: The phenotype of seizure clustering with febrile illnesses in infancy/early childhood is well-
recognized. To date the only genetic epilepsy consistently associated with this phenotype is PCDH19, an 
X-linked disorder restricted to females, and males with mosaicism. 
The SMC1A gene, which encodes a structural component of the cohesin complex is also located on the X 
chromosome. Missense variants and small in frame deletions of SMC1A cause approximately 5% of 
Cornelia de Lange Syndrome (CdLS). 
Recently, protein truncating mutations in SMC1A have been reported in five females, all of whom have 
been affected by a drug-resistant epilepsy, and severe developmental impairment. Our objective was to 
further delineate the phenotype of SMC1A truncation. 
Method: Female cases with de novo truncation mutations in SMC1A were identified from the 
Deciphering Developmental Disorders (DDD) study (n=8), from postmortem testing of an affected twin 
(n=1), and from clinical testing with an epilepsy gene panel (n=1). Detailed information on the 
phenotype in each case was obtained. 
Results: 10 cases with heterozygous de novo mutations in the SMC1A gene are presented. All 10 
mutations identified are predicted to result in premature truncation of the SMC1A protein. All cases are 
female, and none had a clinical diagnosis of CdLS. They presented with onset of epileptic seizures 
between <4 weeks and 28 months of age. In the majority of cases a marked preponderance for seizures 
to occur in clusters was noted. Seizure clusters were associated with developmental regression. In all 
cases moderate or severe developmental impairment was apparent. 
Significance: Truncation mutations in SMC1A cause a severe epilepsy phenotype with cluster seizures in 
females. These mutations are likely to be non-viable in males.  
Introduction 
A number of X-linked epilepsies in which females are exclusively, or disproportionately, affected have 
been described. The most well-delineated is PCDH19-related epilepsy, a condition which typically 
presents with fever-sensitive focal seizures, often occurring in clusters, and in which developmental 
problems often become apparent after epilepsy-onset1. Other examples include CDKL52, KIAA20223, 
HNRNPH24, and CASK5. In contrast to PCDH19, in which (non-mosaic) male mutation carriers are usually 
asymptomatic, in CDKL5, HNRNPH2, KIAA2022, and CASK, males are presumed to be non-viable, though 
rare cases of more severely affected males have been described in CDKL5, KIAA2022, and CASK2,3,5. 
The SMC1A gene, located at Xp11.22, encodes one of four core subunits that make up the cohesin ring. 
The cohesin ring plays important roles in cell division, transcription regulation, and DNA repair6. 
Derangements of the cohesin ring are known to cause Cornelia de Lange syndrome (CdLS), a 
multisystem developmental disorder first described in 18497. Affected individuals are typically 
microcephalic with striking pre- and postnatal growth restriction often associated with feeding 
difficulties and gastro-esophageal reflux8. They have a characteristic facial appearance with fine arched 
eyebrows, synophrys, long philtrum, thin upper vermilion and low set posteriorly rotated ears and 
variable presence of malformations (limb, cardiac, diaphragmatic, gastrointestinal and genitourinary). 
The reported prevalence of epilepsy ranges from 4 to 23%, with no particular seizure pattern described9. 
Approximately 65% of CdLS cases are caused by mutations in genes (NIPBL, SMC1A, SMC3, RAD21, and 
HDAC8) which encode structural components or regulators of the cohesin ring10. To date 60 cases of 
CdLS due to SMC1A mutation have been described, with a male:female ratio of 1:211. All reported 
variants have been missense mutations or small in-frame deletions. This led to the previous hypothesis 
that mutations causing truncation of the SMC1A protein would be either asymptomatic or non-viable11. 
The absence of SMC1A protein truncating mutations in large databases comprised largely of 
asymptomatic individuals favored the hypothesis that they would be non-viable12.  However, recently, 
SMC1A truncation mutations have been described in five cases, all female, none of whom had a clinical 
diagnosis of CdLS13-15. All five cases developed drug-resistant epilepsy and had severe developmental 
impairment. Age at presentation with first epileptic seizure ranged from <1 month to 17 months. 4/5 
cases were reported to have a clustering pattern to the seizures.  
Here we report the phenotypes of 10 new cases of SMC1A truncation related epilepsy, further 
delineating the phenotype. Our data help further define SMC1A truncation as a genetic epilepsy with 
distinct electro-clinical features, that can occur in cases without typical features of CdLS. We propose 
that, along with PCDH19, testing of the SMC1A gene should be considered in females with early 
childhood onset drug-resistant epilepsy, particularly where there is a clustering pattern to the seizures. 
Methods 
Ethical compliance: 
The DDD study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge 
South REC, and GEN/284/12 granted by the Republic of Ireland REC). 
Case Ascertainment: 
8 of the 10 affected cases (cases 1-8) were recruited via UK NHS Regional Genetics Services to the 
Deciphering Developmental Disorders (DDD) project (http://www.ddduk.org/). Case 9 was tested 
postmortem following the genetic result found in her twin sister through DDD. Case 10 was followed in 
pediatric neurology and genetics due to a severe developmental and epileptic encephalopathy. 
A structured proforma, including detailed phenotypic data, was completed by both the clinical geneticist 
and the pediatric neurologist involved in each case; this was used in conjunction with information in the 
DDD database. 
Sequencing and analysis 
For cases 1-8, trio-based exome sequencing was performed as part of the DDD study as previously 
described16,17. Target capture using Agilent SureSelect 55 MB Exome Plus was performed on saliva- or 
blood-derived genomic DNA from each affected case and their parents and sequenced on Illumina 
HiSeq. DeNovoGear21 was used to identify de novo sequence variants and Ensembl Variant Effect 
Predictor (VEP version 2.6, http://www.ensembl.org/info/docs/tools/vep/index.html) was used to 
predict the effect of each genomic variant. PolyPhen-2 analysis was carried out at 
http://genetics.bwh.harvard.edu/pph2/. SIFT analysis was carried out at http://sift.bii.a-
star.edu.sg/www/SIFT_seq_submit2.html(parameters used: Database UniProt-SwissProt2010_09; 
Median conservation of sequences 3.00; Remove sequences more than 90% identical). Genbank 
accession for SMC1A is NM_006306. 
Case 9 was post mortem sequenced locally for the variant found in her sister following her sister’s result 
through DDD. Case 10 was tested using a custom gene panel of >100 candidate genes or genes 
associated with the epileptic encephalopathy, microcephaly and genetic syndromes with seizures. 
Results 
Clinical findings 
We obtained detailed phenotypic information on nine cases with SMC1A truncation. A further case who 
was more severely affected than all of the others (case 9), was the older sister of case 8. Case 9 died at 
aged 11 months. We were unable to obtain details of her epilepsy other than that she began having 
seizures in the neonatal period. She had semilobar holoprosencephaly, partial anomalous pulmonary 
venous drainage, and dysmorphic facial features. Her sister, with the same mutation, had no structural 
organ anomalies, no dysmorphic features, and a normal MRI brain scan. All 10 cases identified were 
female, and they all presented with a drug-resistant epilepsy, though two cases eventually became 
seizure-free (case 2 from aged five years, and case 4 from aged seven years).  Prior to, and after, their 
genetic diagnosis, none were considered as having Cornelia de Lange syndrome (see Supplementary 
Material for further clinical details of each case). 
Development 
Apart from the two cases who began having seizures in the neonatal period, concerns about 
developmental delay had clearly arisen prior to the onset of epileptic seizures. All 10 cases have 
moderate, severe, or profound developmental impairment, with all domains of development affected. 
None of the cases had any expressive language. One case (case 6) did develop babbling between one 
and two years of age before losing this ability following a 45-minute episode of tonic-clonic status 
epilepticus at the age of three years. None of the other cases were felt to have had any regression in 
their development associated with either epilepsy onset, or any period of poor seizure control. Four of 
the 10 cases have achieved independent mobility, albeit with significant delay. Three of the 10 cases 
have cerebral visual impairment. 
Seizures 
Age of onset of first seizure ranged from the neonatal period to 28 months of age (median 4.5 months). 
The first epileptic seizure was an afebrile generalized motor seizure (generalized tonic-clonic, or 
generalized clonic) in five cases, a focal seizure in two cases, a generalized tonic seizure in one case, and 
generalized tonic-clonic febrile convulsion in one case. Seven cases demonstrated both focal and 
generalized seizure types, whilst two cases had generalized seizures only. Seven cases demonstrated a 
clear predisposition for seizures to occur in clusters. For example, case 6 currently has clusters of 
between three and 10 focal-onset seizures, occurring over a period of 24 hours, every 10-21 days, with 
complete seizure-freedom between clusters. Case 8 has clusters of 6-7 generalized tonic-clonic seizures 
occurring two to three times per month. Two cases have had episodes of convulsive status epilepticus, 
and one case has had episodes of non-convulsive status epilepticus. 
Electroencephalogram (EEG) 
All nine cases for whom we have seen EEGs or EEG reports have demonstrated focal or multifocal 
abnormalities. Typically, the interictal EEGs show independent multifocal spike and sharp-wave 
complexes seen in both awake and sleep recordings (see figures 6 and 8), as well as subclinical runs of 
generalized spike-wave abnormalities, lasting several seconds (Figure 1A). Ictal EEGs show generalized 
slowing of background (Figure 1C), followed by focal spike discharge widely distributed over one 
hemisphere (Figure 1E). In other EEGs in the same case the spike discharge may be over the other 
hemisphere.  
Epilepsy treatment 
From this small case series, no single anti-epileptic medication has emerged as clearly more efficacious 
than others. In fact, though six of the referrers reported one or more anti-epileptic medication to be 
particularly efficacious in their case, in all six cases this was a different drug. One case became seizure-
free shortly after introduction of Phenobarbitone, one case became seizure-free shortly after 
introduction of Gabapentin, and one case achieved seizure-freedom for one year after Levetiracetam 
was started. In all cases multiple medications were tried (range 4-8). Three have tried the ketogenic diet, 
two of whom were felt to benefit significantly in terms of seizure-control, and one of whom remains on 
it at present (after 4.5 years). Two have tried vagus nerve stimulation, both without perceived benefit. 
Growth 
Short stature and progressive microcephaly were seen in the majority of cases. Overall, height and head 
circumference are proportionally small. Most recent height measurement was >2 Z-scores in 7/9 cases 
below the mean on most recent height measurement, and mean most recent height was -3.0 Z-scores 
(SD 1.5). None of the cases had microcephaly at birth, though mean birth occipito-frontal circumference 
(OFC) was -1.5 Z-scores below the mean. Most recent OFC was >2 Z scores below the mean in 8/9 cases, 
with a mean most recent OFC of -3.0 Z-scores (SD 1.6). The cases also demonstrated a deceleration in 
weight gain. Only 1/10 cases had a low birth weight (>2 Z-scores below the mean), though mean birth 
weight for the 10 cases was -1.29 Z-scores (SD 0.67). However, in 5/9 cases the most recent weight was 
>2 Z-scores below then mean, and the mean most recent weight for the group was -2.2 Z-scores (SD 
1.4). 
Dysmorphism and associated anomalies 
Two cases have no dysmorphic features and no congenital anomalies, and another one has dysmorphic 
features but no congenital anomalies. Four cases have congenital cardiac anomalies: two atrial septal 
defect plus ventricular septal defect, one atrial septal defect only, and one partial anomalous pulmonary 
venous drainage. Two cases have had cleft palate, and two have bifid thoracic vertebrae. From 
photographs the primary authors have seen, there appears to be a characteristic facial appearance, 
consisting of a flattened mid-face, a short, upturned nose, and a shallow philtrum (Figure 2). 
Genetic findings 
The phenotypic findings of the 10 cases from our study, along with those of the previously reported 5 
cases are summarized in Table 1. The genetic findings of the 10 new cases are summarized in Table 2. In 
all 10 cases the mutation had arisen de novo and was predicted to lead to premature truncation of the 
SMC1A protein. 
Discussion 
Analysis of the 10 cases reported here, and the previously published five cases, allows delineation of a 
distinct epilepsy phenotype associated with SMC1A truncation mutations. Eight of our 10 cases were 
recruited from a large cohort who had been referred for genetic investigation of a developmental 
disorder (the DDD study), not specifically for epilepsy17. Despite the broad entry criteria for the DDD 
study, all the SMC1A truncation cases identified from this cohort have been found to have a severe 
drug-resistant epilepsy, suggesting that the correlation between SMC1A truncation and the epilepsy 
phenotype is strong. All five previously reported cases in the literature also had drug-resistant epilepsy13-
15. Additionally, Hansen et al. reported a female with a de novo splice-site mutation in SMC1A who had 
infantile-onset epilepsy characterized by convulsive seizures “occurring in impressive clusters lasting 24-
48 hours18.” In their discussion Hansen et al. commented that although the diagnosis of Cornelia de 
Lange syndrome was not considered initially, “retrospectively the girl’s symptoms and facial gestalt 
[were] compatible with mild Cornelia de Lange syndrome (CdLS).” We argue that SMC1A truncation 
does not represent a mild form for CdLS since these females are affected by a more severe 
developmental disorder than is typical for CdLS caused by SMC1A variants.  
The presence of seizure clustering is a strong theme that has emerged in our cases. 7/10 cases were 
noted to have seizure-clustering. Seizure clustering was also noted in 4/5 of the previously reported 
cases. The only other genetic epilepsy for which seizure clustering has emerged as a prominent feature 
is PCDH19-related epilepsy. As with SMC1A, PCDH19 related epilepsy is an X-linked disorder, affecting 
mostly females. The PCDH19 phenotype has now been well-defined, and can be summarized as follows:  
Normal development before onset of seizures; seizure onset between 3 months and 3 years (median 11 
months)19; clusters of convulsive seizures which are markedly fever-sensitive; progression to multiple 
seizure types including focal seizures and absences1. Developmental stagnation or regression may be 
noted after epilepsy onset, though up to 40% of PCDH19 cases continue to have normal 
development19,20. Dysmorphism and malformation are not commonly associated with PCDH1921. 
Epilepsy onset and seizure clustering is remarkably similar in these SMC1A cases to that seen in PCDH19-
related epilepsy. Seizure onset was from <4 weeks to 28 months (median 5 months). Though bilateral 
motor seizures predominated, 9/15 had multiple seizure types. Despite certain similarities, a number of 
features distinguish SMC1A truncation-related epilepsy from PCDH19. From our 10 cases and the 5 
previously reported cases, 12/15 were noted to have dysmorphic features and 6/15 had malformations 
(cardiac, vertebral, palatal). These cases are also notable for short stature, a marked progressive 
microcephaly, and for the presence of a moderate to severe developmental impairment which clearly 
preceded seizures in those cases with later-onset epilepsy. In terms of their epileptic seizures, these 
SMC1A truncation cases do not appear to demonstrate the same degree of fever-sensitivity as is seen in 
PCDH19. Furthermore, myoclonic seizures, hemiclonic seizures, and tonic seizures were reported in 
multiple cases in this series, but these seizure types are not typically seen in PCDH19-related epilepsy20. 
There are phenotypic similarities between the cases reported here and CdLS, including short stature, 
microcephaly and developmental delay, as well as dysmorphic features and congenital anomalies in 
some. Four of our cases had structural cardiac anomalies, including atrial septal defect (ASD) and 
ventricular septal defect (VSD). A wide variety of structural cardiac defects are seen in CdLS, including 
ASD and VSD. Pulmonary stenosis, not seen in any of our cases, is the most frequently reported 
cardiovascular anomaly in CdLS22,23. Bifid vertebrae, seen in two of our cases, are not a frequently 
reported feature of CdLS11. 
What appears to distinguish SMC1A truncation carriers most from the typical CdLS phenotype is the 
absence of the characteristic facial features, and the severity of the epilepsy and developmental 
disorder.  Though not a core feature of the syndrome, epilepsy is seen more frequently in CdLS than in 
the general population, with the estimated prevalence in various reports ranging from 4% to 23%9. 
Though epilepsy does not appear to be more frequently seen in SMC1A-related CdLS compared to CdLS 
due to mutations in other cohesin complex genes10, it is notable that the majority of, though not all, 
male SMC1A cases reported have epilepsy as a feature24-27.  
Whether SMC1A truncation should be considered a separate entity to CdLS, or as a subtype of CdLS, is a 
matter for debate. Importantly, we have shown that SMC1A truncation can cause a severe 
developmental disorder and drug-resistant epilepsy in cases where CdLS was not otherwise considered. 
This may have implications for practice when clinicians are considering, and interpreting, genetic testing. 
The underlying pathophysiology of CdLS caused by SMC1A mutations is not fully understood. SMC1A is a 
structural component of the cohesin ring, which binds to chromatin and plays an important role in the 
transcriptional regulation of a large number of other genes28. There are 60 published cases of SMC1A-
related CdLS (35 female and 25 male), and all reported variants are either missense variants, or 
deletions that preserve the reading frame of the protein11,24-27, 29-33.  In those cases in which there is 
familial inheritance of an SMC1A mutation, males demonstrate a more severe phenotype than 
females24. Functional studies using human lymphoblastoid cell lines of CdLS patients and healthy 
controls have demonstrated that in CdLS mutant SMC1A is almost fully transcribed and incorporated 
into the cohesin complex29. Since mutant SMC1A would be present in all male cells, whereas in females 
it would only be present in those cells in which the mutated SMC1A allele is not inactivated, this could 
explain why male SMC1A CdLS patients appear to be more severely affected than females within the 
same family. However, SMC1A appears to escape inactivation in some, but not all, females34, leading to 
a hypothesis that mutant SMC1A may exert a dominant negative effect in female CdLS cases35. 
The absence of any reported males with SMC1A truncation mutations implies that complete SMC1A 
deficiency is incompatible with viability. The mechanism of pathogenesis in females with SMC1A 
truncation can only be speculated. Lebrun et al.15 demonstrated that in their female case of SMC1A loss-
of-function there was a reduced level of SMC1A transcript. However, if SMC1A does escape X-
inactivation then haploinsufficiency is unlikely to be the causative mechanism since female 
haploinsufficient cells would have the equivalent of a normal male complement of SMC1A36. It is 
possible that truncated SMC1A is transcribed and translated, escapes nonsense-mediated decay, and 
exerts a dominant negative effect.  To gain a greater understanding of the mechanism would require full 
investigation of human SMC1A inactivation (including specifically in relevant tissues) and the extent to 
which truncated transcripts undergo nonsense mediated decay. Another valuable line of inquiry would 
be further definition of the role of SMC1A as a transcriptional regulator, whether such transcriptional 
regulation follows a cyclical pattern, and how this may relate to the clustering pattern of seizures seen. 
Finally, it is interesting to note that despite a recent proliferation of large exome sequencing studies 
investigating children with early-onset epilepsy, SMC1A has not emerged as an important gene until 
now. One reason for this may be that recruitment to previous studies has focused on defined electro-
clinical syndromes such as Ohtahara Syndrome, Infantile Spasms, Dravet Syndrome, Lennox Gastaut 
Syndrome, and Epilepsy with Myoclonic Atonic Seizures37-41. This series demonstrates that through the 
investigation of a broader group of children with developmental disorders, genetic syndromes with well-
defined phenotypes can emerge.  
Summary 
SMC1A truncation mutations are only seen in females, and cause a condition in which the typical 
features of Cornelia de Lange syndrome are often absent. These females are all affected by a moderate-
to-severe developmental impairment and a drug-resistant epilepsy which characteristically 
demonstrates a clustering pattern. Further investigation into how SMC1A truncation leads to this 
phenotype is required. It is likely that disrupted transcriptional regulation of other genes plays an 
important role. 
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Key points 
 Truncation mutations in SMC1A have only been reported in females 
 This series takes the total number of published cases to 15  
 Early-childhood onset epilepsy and moderate-severe intellectual disability is seen in all cases  
 Focal and generalized seizures are seen 
 Seizures frequently occur in clusters, without a clear precipitant to the clusters 
 Cases often lack the typical features of Cornelia de Lange Syndrome, which is caused by 
missense mutations in SMC1A 
  
Figures and tables 
 Table 1  - Summary of the phenotypic features from our 10 cases and the previously reported 5 
cases 
 Table 2 - Summary of genetic findings from our 10 cases 
 Figure 1- EEGs from 3 cases 
o (A) Inter ictal sleep EEG from case 1: showing generalised irregular spike/sharp and slow 
activity in sleep without any clinical accompaniment 
o (B) Inter ictal EEG from case 6: showing short bursts of mixed spike and slow waves with 
a bilateral but asymmetric distribution 
o (C) Ictal EEG from case 6 during a focal-onset seizure: showing generalized spike and 
slow wave activity 
o (D) Inter ictal EEG from case 10: showing irregular spike/sharp and slow wave activity, 
more prominent in the left temporal and occipital regions 
o (E) Ictal EEG from case 10: showing right sided sharp waves and left sided slow waves 
 Figure 2 – Facial appearances, from left to right: case 6, case 4, case 8, case 10 
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Case Base change Amino acid change Predicted effect 
on protein 
Zygosity Inheritance X-
inactivation 
studies 
1 c.1591C>T 
 
p.Gln531Ter 
 
Truncation Heterozygous De novo Moderately 
skewed 
2 c.3145C>T 
 
p.Arg1049Ter Truncation Heterozygous De novo Not done 
3 c.549G>A  pGlu183Glu Splice site 
interference 
Heterozygous De novo Not done 
4 c.2197G>T p.Glu733Ter Truncation Heterozygous De novo Normal 
5 c.3326_3330delA
TGGC insC 
p.Asp1109AlafsTer102 Truncation Heterozygous De novo Not done 
6 c.2923C>T 
 
p.Arg975Ter Truncation Heterozygous De novo Not done 
7 c.511C>T 
 
p.Arg171Ter 
 
Truncation Heterozygous De novo Normal 
8 c.2477delA 
 
Frameshift Truncation Heterozygous De novo Not done 
9 c.2477delA 
 
Frameshift Truncation Heterozygous De novo Not done 
10 c.3115C>T p.Gln1039Ter Truncation Heterozygous De novo 76:24 ratio in 
blood 
Table 1 - summary of genetic findings from our 10 cases 
 
Subject 1 
Subject 1 is a 6-year-old female. She was born at 34 weeks’ gestation weighing 1420g (-1.8 SD), and 
with OFC of 29.5cm (-0.8 SD). There was established intrauterine growth restriction. Tone was 
normal for gestation at birth, but 3 weeks of feeding support via nasogastric tube were required. 
Gross motor delay became apparent at 6 months of age when she was unable to roll. She was first 
able to sit at 2 years of age, and she began walking at 2.5 years. She can now run with an unsteady 
gait, but she requires assistance to get to standing from sitting. She spoke her first words at 4 years. 
At one stage she had 6 words but has since lost them. She is sociable, happy and content. She makes 
hand gestures and responds to music with a smile. She eats pureed food only and is able to feed 
herself with a spoon. 
She presented with a cluster of generalized tonic-clonic seizures (GTCS) at 15 months of age. On this 
occasion she had 5-6 seizures in a 3-day period. She was initially started on Phenytoin and Sodium 
Valproate and was seizure-free for 10 months. She now has clusters of nocturnal GTCS or hemiclonic 
seizures every 6 weeks with no obvious precipitant to clusters. She is currently taking Topiramate, 
Clobazam and Carbamazepine regularly. The hemiclonic seizures can affect either her left or right 
side. The following antiepileptic medications have all been tried but none have controlled seizures: 
Levetiracetam, Lamotrigine, Clobazam, Topiramate. 2 MRI brain scans have been normal. EEGs have 
shown independent left and right sided anterior epileptiform abnormalities, with sleep activation 
and runs of fairly generalised epileptic activity. 
She has mild facial asymmetry with the right side of the face appearing fuller than the left. There is 
mild left ptosis and she has small hands and feet. Current height is 103.6cm (-2.3 SD), weight is 
14.35kg (-3.0 SD), and occipito-frontal circumference (OFC) 48.5cm (-3.0 to -4.0 SD).  She has low 
muscle tone and hypermobility.  
Subject 2 
Subject 2 is a 6-year-old female. She was born at T+12 weighing 3345g (-0.9 SD). OFC at birth was 
33.7cm (-1.47 SD). At 4-5 months of age she was found to have significant hypotonia. She has severe 
developmental impairment. At the age of 6 years she is unable to sit independently, she has no 
meaningful use of her hands, and no verbal or non-verbal communication. She has had severe 
gastro-oesophgeal reflux, treated by gastrostomy and fundoplication. She has bilateral congenital 
hip dysplasia, bilateral talipes equinovarus, and a bifid T8 vertebra.  
She presented with a seizure at 5-6 weeks of age. Initial seizures were described as tonic-clonic, but 
she went on to have focal seizures characterized by right facial drooping and cycling arm 
movements. Most seizures have been accompanied by apnoea. Seizures initially occurred every 2-3 
days and were resistant to multiple therapeutic interventions, including Carbamazepine, Sodium 
Valproate, Topiramate, Clobazam, Rufinamide, Ketogenic Diet, and Vagal Nerve Stimulation. 
Levetiracetam made seizures markedly worse. She was started on Gabapentin at the age of 5 years 
10 months and has been seizure-free since then. MRI brain at 4 months was normal, but at 5 years 
showed progressive cerebral volume loss. EEGs were initially normal, but more recently have been 
diffusely slow with sharp transients seen over both temporal regions.  
She has marked bitemporal narrowing; upslanting palpebral fissures; fairly thin, straight eyebrows; 
slightly coarse facial features; mildly posteriorly rotated ears; mild tapering of her digits; slightly 
short 5th fingers; short broad halluces; and overlapping of the 2nd and 3rd toes. Most recent 
measurements aged 34 months were: length 83cm (-2.6 SD) weight 10.9kg (-2.1 SD), and OFC 
40.8cm (-4.5 SD). 
Subject 3 
Subject 3 is a 3-year-old female. She was born at term weighing 3160g (-0.5 SD). OFC was not 
recorded at birth but was 38.5cm at 12 weeks of age (-1.6 SD). Following suction stimulation and 
oxygen for thick meconium at delivery, she was treated with incubator oxygen for the first 8 hours of 
life. A cleft palate was present at birth. There were neonatal feeding difficulties requiring nasogastric 
tube feeding. By day 35 of life she was bottle feeding by day, with overnight nasogastric feeds. She 
has severe global developmental delay. She rolled at 7 months, but will only occasionally do so. She 
is able to bring her hands together and clap, but is unable to hold anything in her hands. At aged 3 
years she cannot sit without support and has poor head control. She has no words but can laugh, 
giggle and babble, and is socially responsive. She has cerebral visual impairment, fixing and following 
only fleetingly,  and bilateral conductive hearing loss. She suffers with chronic constipation. Renal 
USS shows multiple small cysts. 
Her first seizure was at 4 months of age and was characterised by bilateral upper limb stiffening, 
frothing of the mouth, and cyanosis. She has clusters of seizures which build up over several days 
and often require hospital admission for emergency management. Seizures have been refractory to 
Gabapentin, Acetazolamide, Clonazepam, Lorazepam, Sodium Valproate, Levitiracetam, Pyridoxine, 
and Phenobarbital. Introduction of Stiripentol was felt to improve seizure control. MRI brain showed 
a small hemorrhage along the posterior falx and tentorium thought possibly related to delivery. 
Repeat MRI scan showed normal myelination  with diffuse reduced volume of the brain matter in 
the supra and infra tentorial levels. EEG shows high amplitude background activity and epileptiform 
discharges over left and occasionally right hemisphere. 
She has truncal hypotonia with slightly increased limb tone, normal deep tendon reflexes, bilateral 
ankle clonus and downgoing plantar reflexes. She has hirsutism of the forehead, back, arms and 
upper lip, bitemporal narrowing with low anterior hairline, long eyelashes, and downturned corner 
of mouth with midline groove of the lower lip. Most recent measurements, at aged 40 months, are: 
height 97.9cm (0.06 SD), weight 14.8kg (-0.04SD) and (OFC is 47.3cm (-0.8 SD). 
Subject 4 
Subject 4 is an 8-year-old female. She was born at term weighing 3220g (-0.4 SD). OFC at birth was 
32cm (-2.0 SD) and had dropped to below -2.0 SD by 8 months of age. She required nasogastric 
feeding support for the first 2 months of life. She has severe developmental impairment, with no 
verbal communication and no independent mobility at the age of 8 years. She has a diagnosis of 
autism spectrum disorder. She had an atrial septal and ventricular septal defect repaired in infancy.  
Her first seizure was at 5 months of age. She had tonic posturing with head turning to the right 
followed by 4 limb clonic movements lasting 2 minutes. She continued to have similar seizures 
approximately every 2 days. She also developed generalised tonic seizures and seizures with 
unresponsive stares, considered most likely to be focal seizures.  She had unprecipitated clusters of 
seizures. Skill loss was noted following seizure clusters. Her epilepsy was refractory to Sodium 
Valproate, Lamotrigine, Carbamazepine, Topiramate, Levetiracetam and Phenytoin. She had a period 
of control on Clobazam which then lost its effect. She has been seizure-free since commencing 
Phenobarbital. MRI brain is normal. Interictal EEG shows multifocal epileptic activity, ictal EEG has 
demonstrated right temporal lobe seizure-onset. 
She has small widely spaced teeth, deep-set eyes, downward sloping palpebral fissures, and 
syndactyly of the 1st and 2nd toes. Most recent measurements were OFC 46.0cm at aged 49 months 
(2-3 SD below mean), height 74cm at aged 20 months (-2.6 SD) weight 7.9kg at aged 20 months (-4.0 
SD). Examination reveals low tone with normal deep tendon reflexes.  
Subject 5 
Subject 5 is a 10-year-old female. A cerebral cystic lesion and abnormal positioning of the halluces 
were noted antenatally. She was born at term weighing 3005g (-0.9 SD). OFC at birth was 33cm (-1.2 
SD) but fell to > 2.0 SD below the mean by 4 months of age. The cystic brain lesion was confirmed 
postnatally on MRI brain to be a cavum septum vergae. She has severe developmental impairment. 
She is unable to walk or to sit independently. She has no verbal communication and is unable to feed 
herself. She has cortical visual impairment. A gastrostomy was inserted at the age of 2 years. She has 
a bifid T6 vertebra, a small intra-atrial defect, and has been operated on for choanal atresia and 
stenosis which were contributing to episodes of stridor with cyanosis.  
There was a plateauing of development prior to her presentation with seizures. She had clusters of 
eye twitching, limb-shaking, and impaired awareness.  She presented with a cluster of 19 seizuresin 
a 24-hour period at the age of 6 months. EEGs showed continuous high voltage waves without 
epileptiform discharges. She subsequently developed myoclonic seizures, absence seizures, tonic 
seizures, epileptic spasms, and reflex seizures to sensory stimuli.  She has had several episodes of 
non-convulsive status epilepticus and status myoclonus. Seizure clusters are precipitated by urinary 
tract infections. Seizures have been refractory to Phenobarbital, Carbamazepine, Clobazam, Sodium 
Valproate, Lamotrigine, Topiramate, Levetiracetam, and Pyridoxine,. Phenobarbital and Clobazam 
have been helpful as rescue therapy, whilst Paraldehyde and Clobazam have been helpful for seizure 
clusters. The use of the classical ketogenic diet reduced seizures significantly and allowed weaning of 
maintenance AEDs.  
Subject 6 
Subject 6 is a 5-year-old female. She was born at term weighing 2325g (-2.5 SD). OFC was -4.7 SD 8 
weeks of age. Concerns about her visual behavior and lack of fine motor activity were noted at 6 
months of age. She has global developmental delay. She was able to sit unsupported at 12 months 
and to walk at 30 months. She began babbling at 1-2 years of age but all verbal communication 
stopped following a 45-minute seizure at age 3 years. 
Her first seizure was at 5 months of age. Her arms went stiff, with eyes deviated to the left, and loss 
of awareness. Subsequently she developed seizures with the same onset, but followed by clonic 
movements of all 4 limbs. She continued to have seizures like this, occurring in clusters of 3-10 
seizures in a 24-hour period, every 10-21 days. Seizures have been refractory to Carbamazepine, 
Sodium Valproate, Topiramate, and Phenobarbital. She was seizure-free for 1 year on Levetiracetam 
before recurrence, and she had significant reduction in seizure frequency on the Ketogenic diet. MRI 
brain is normal. EEG demonstrates a high voltage slow background. Ictally there are bilateral bursts 
of high voltage slow waves with spikes and polyspikes intermixed. 
She has puffy eyes; right nasal deviation; a small inturned right pinna; clinodactyly of the middle toes 
of both feet; and a central incisor. Current measurements are: height 97cm (-3.2 SD), weight 12.2kg 
(-4.2 SD), OFC (<-3 SD). Examination reveals generalized hypotonia with intact deep tendon reflexes. 
Subject 7 
Subject 7 is a 4-year-old female. She was born at term weighing 2722g (-1.5 SD). OFC was -1.3 SD.  
Her first seizure at 4 weeks’ of age was a generalised seizure, characterised by clonic movements of 
all 4 limbs and the eyelids. She had had loose stools for a day before onset. Initial EEG was normal. 
By 6 months she was having tonic seizures sometimes in clusters and sometimes followed by a 
bilateral clonic phase. OFC was already on -2SD.The EEG then showed frequent multi spike and slow 
on the right centro-temporal region.  
She has continued to have clusters of tonic-clonic seizures from September 2014, which did not 
respond to the addition of Topiramate, Valproate or Lamotrigine. Seizures can be unilateral right 
sided or left sided and have been followed by a right-sided Todd’s paresis. 
At 8 months she had poor muscle tone and gross motor delay. All developmental milestones have 
been delayed. At the age of 3 years 11 months she was just able to take a couple of steps holding 
onto a hand. She is sociable. She has no words but does coo, laugh, and cry appropriately. She shows 
limited social interaction and demonstrates no understanding of language with no meaningful 
communication gestures or words. Most recently she has lost interest in feeding despite having a 
safe swallow and requires PEG insertion. She is generally hypotonic but with increased dynamic tone 
at the ankle. 
Measurements at 27 months of age were: height 78.8cm (- 2.5 SD), weight 10.8kg (-1.5 SD), and OFC 
44.9cm (-2.0 SD). She has no dysmorphic features or malformations. 
Subject 8 
Subject 8 is a 14-year-old female. She was a twin born at 37 weeks’ gestation. Birth weight was 
2.324kg (-1.2 SD). She presented with delayed walking at > 2 years of age. She has severe 
developmental impairment and was diagnosed with autism at the age of 5 years. At the age of 7 
years she had no verbal communication. 
At 28 months of age she had a febrile convulsion. Following that she went on to have clusters of 
generalized tonic-clonic seizures 2-3 times per month, with 6-7 seizures in each cluster. Her seizures 
have been refractory to Phenobarbital, Levetiracetam, Topiramate, Lamotrigine, Carbamazepine, 
Clobazam, and Vagal Nerve Stimulation. MRI brain is normal. Sleep-deprived EEG shows right-sided 
spike and slow wave abnormalities.  
Measurements at 6 years + 9 months of age were: height 102cm (-3.7 SD), weight 16.4kg (-2.4 SD), 
OFC 48.0cm (<-2.0 SD). She has no dysmorphic features or malformations. 
Subject 9 
Subject 9 is the twin sister of case 8. She was born at 37 weeks’ gestation weighing 2000g (-2.0 SD). 
OFC at birth was 30.5cm (-1.7 SD). Multiple congenital anomalies were identifiable at birth including: 
hypotelorism; small low-set posteriorly rotated ears; bilateral 5th finger clinodactyly; overlapping 4th 
and 5th fingers; left rockerbottom foot; and hypoplastic nails of the 4th and 5th toes. She had 
semilobarholoprosencephaly and partial anomalous pulmonary venous drainage. She had refractory 
neonatal seizures and she died at the age of 11 months. 
Subject 10 
Subject 10 died at the age of 9 years and 10 months. She was born at T+14 weighing 3185g (-1.2 SD). 
OFC at birth was 34cm (-1.3 SD). She had severe hypotonia that persisted throughout life. She was 
nasogastric tube fed from birth until 3 years of age when a gastrostomy tube was placed. She made 
very little developmental progress, was never able to sit, reach for objects, or communicate. She had 
atrial septal and ventricular septal defects repaired at 6 weeks’ of age. 
Her first seizure was at 2 months of age and was a generalized tonic-clonic seizure. These seizures 
continued to occur daily. From 6 months of age she developed myoclonic seizures occurring daily. 
She had episodes of status epilepticus 2-3 times per year. Seizures were refractory to Topiramate, 
Sodium Valproate, Leveiracetam, and Rufinamide. Serial MRI brain scans showed a thin abnormally 
shaped carpus callosum and minimal cerebral atrophy. Interictal EEG showed multifocal 
epileptogenic activity, more often over the right hemisphere.  
Straight eyebrows and low set ears were noted at birth. Most recent measurements at 8 years and 6 
months were: height 102.5cm (-5.0 SD), weight 16.1kg (-0.5 SD), OFC 43.7cm (-6.3 SD). She died of 
aspiration pneumonia. 
